Log in to save to my catalogue

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for tr...

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for tr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2be29bc5fe7543e09a2cd42ab1b3c8f2

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

About this item

Full title

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

Publisher

New Zealand: Dove Medical Press Limited

Journal title

Vascular health and risk management, 2014-01, Vol.10 (default), p.75-87

Language

English

Formats

Publication information

Publisher

New Zealand: Dove Medical Press Limited

More information

Scope and Contents

Contents

In 1995, the NINDS (National Institute of Neurological Disorders and Stroke) tPA (tissue plasminogen activator) Stroke Study Group published the results of a large multicenter clinical trial demonstrating efficacy of intravenous tPA by revealing a 30% relative risk reduction (absolute risk reduction 11%-15%) compared with placebo at 90 days in the...

Alternative Titles

Full title

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2be29bc5fe7543e09a2cd42ab1b3c8f2

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2be29bc5fe7543e09a2cd42ab1b3c8f2

Other Identifiers

ISSN

1178-2048,1176-6344

E-ISSN

1178-2048

DOI

10.2147/VHRM.S39213

How to access this item